EWTXHealthcare · BiotechnologyEWTX Stock Forecast: Edgewise Therapeutics, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering Edgewise Therapeutics, Inc. hold a median 12-month price target of $52 — +35.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 1 Aug 2026 — in the upper half.
EWTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Edgewise Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (79): The shares have been drifting up relative to others.
Growth (33): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Edgewise Therapeutics, Inc. — and when they’d sell — is the membership.
EWTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EWTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +35.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | Evercore ISI Group | Maintains | Outperform | $45 → $55 |
| 9 July 2026 | Oppenheimer | Initiates | Outperform | $51 |
| 9 July 2026 | Oppenheimer | Initiates | Outperform | — |
| 6 July 2026 | Guggenheim | Maintains | Buy | $41 → $51 |
| 6 July 2026 | Guggenheim | Maintains | Buy | — |
| 17 June 2026 | Goldman Sachs | Maintains | Neutral | — |
| 17 June 2026 | RBC Capital | Maintains | Outperform | — |
| 16 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 June 2026 | RBC Capital | Maintains | Outperform | — |
| 2 June 2026 | Wedbush | Maintains | Outperform | — |
| 17 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 17 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 27 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 14 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 7 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 7 Nov 2025 | Wedbush | Maintains | Outperform | — |
| 25 Sept 2025 | Goldman Sachs | Initiates | Neutral | — |
| 19 Aug 2025 | JP Morgan | Maintains | Overweight | — |
| 8 Aug 2025 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
EWTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Edgewise Therapeutics, Inc. (EWTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −23.5×
- Price / sales
- —
- Price / book
- 8.4×
- EV / EBITDA
- −18.4×
Cheaper than 96% of US stocks
Cheaper than 12% of US stocks
Cheaper than 89% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −38.1%
- Return on assets
- −25.6%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
EWTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EWTX appears on the weeks it earns a place.
Frequently asked questions about EWTX stock
What is the EWTX stock price forecast for 2026-2027?
The 12 Wall Street analysts covering Edgewise Therapeutics, Inc. have a median 12-month price target of $52, with estimates ranging from $30 to $66. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EWTX stock a buy right now?
Of the 12 analysts covering Edgewise Therapeutics, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edgewise Therapeutics, Inc. 52 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EWTX?
As at 1 Aug 2026, Edgewise Therapeutics, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).
Will EWTX stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +35.5% from the last close, and Ticker Nerd's factor model ranks Edgewise Therapeutics, Inc. 52 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EWTX stock forecast for 2030?
No analyst covering Edgewise Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EWTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $66 over the next 12 months.
How has EWTX stock performed over the past year?
Edgewise Therapeutics, Inc. returned +168.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Edgewise Therapeutics, Inc. do?
Edgewise Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies targeting rare muscle disorders.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies targeting rare muscle disorders. The company's primary function is to address unmet medical needs in the area of muscular health, specifically aiming to develop treatments for conditions such as Duchenne muscular dystrophy. Edgewise Therapeutics employs a cutting-edge approach by utilizing small molecule drugs to modulate proteins critical to muscle function and health. Operating within the biopharmaceutical industry, Edgewise is part of a niche sector where advancements can lead to significant improvements in patient care. Their efforts contribute to the broader medical and pharmaceutical markets by potentially offering new therapeutic options that can have a profound impact on patients' lives. Market significance is underscored by the ongoing need for effective treatments for rare diseases, which often lack adequate therapeutic solutions. Edgewise Therapeutics is an example of how specialized research and development can drive innovation in healthcare, seeking to transform scientific advancements into life-changing medications.
CEO Dr. Kevin Koch Ph.D. · 154 employees · United States · https://edgewisetx.com